| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A semisynthetic ampicillin-derived acylureido penicillin. [PubChem] |
| Indication |
For the treatment of infections caused by Pseudomonas aeruginosa, Escherichia coli, and Haemophilus influenzae. |
| Pharmacology |
Azlocillin, similar to mezlocillin and piperacillin, is an acylampicillin with an extended spectrum of activity and greater in vitro potency than the carboxy penicillins. Azlocillin demonstrates antibacterial activity against a broad spectrum of bacteria, including Pseudomonas aeruginosa, and, in contrast to most cephalosporins, exhibits activity against enterococci. |
| Affected Organisms |
| • |
Enteric bacteria and other eubacteria |
|
| Biotransformation |
Eliminated predominantly by renal mechanisms, but also undergoes biotransformation within body tissues and intraintestinal degradation by bowel bacteria, with high concentrations found in bile. |
| Absorption |
Not significantly absorbed from the gastrointestinal tract. |
| Half Life |
Mean elimination half-life is 1.3 to 1.5 hours. Longer in neonates, and 2 to 6 hours in patients with renal impairment. |
| Protein Binding |
20 to 46% bound to plasma proteins |
| References |
| • |
Wright AJ: The penicillins. Mayo Clin Proc. 1999 Mar;74(3):290-307.
[Pubmed]
|
|
| External Links |
|